Human pluripotent stem cell models of autism spectrum disorder: emerging frontiers, opportunities, and challenges towards neuronal networks in a dish

Stefan Aigner · Tobias Heckel · Jitao D. Zhang · Laura C. Andreae · Ravi Jagasia

Received: 16 April 2013 / Accepted: 10 October 2013 / Published online: 14 November 2013 © The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract Autism spectrum disorder (ASD) is characterized by deficits in language development and social cognition and the manifestation of repetitive and restrictive behaviors. Despite recent major advances, our understanding of the pathophysiological mechanisms leading to ASD is limited. Although most ASD cases have unknown genetic underpinnings, animal and human cellular models of several rare, genetically defined syndromic forms of ASD have provided evidence for shared pathophysiological mechanisms that may extend to idiopathic cases. Here, we review our current knowledge of the genetic basis and molecular etiology of ASD and highlight how human pluripotent stem cell-based disease models have the potential to advance our understanding of molecular dysfunction. We summarize landmark studies in which neuronal cell populations generated from human embryonic stem cells and patient-derived induced pluripotent stem cells have served to model disease mechanisms, and we discuss recent technological advances that may ultimately allow in vitro modeling of specific human neuronal circuitry dysfunction in ASD. We propose that these advances now offer an unprecedented opportunity to help better understand ASD pathophysiology. This should ultimately enable the development of cellular models for ASD, allowing drug screening and the identification of molecular biomarkers for patient stratification.

Keywords Autism · Autism spectrum disorder · Human pluripotent stem cells · Human embryonic stem cells · Disease modeling · Induced pluripotent stem cell · Neuronal differentiation · Neurogenesis

Abbreviations

ASD Autism spectrum disorder
BDNF Brain-derived neurotrophic factor
CNV Copy number variation
E/I Excitatory/inhibitory
FACS Fluorescence-activated cell sorting
FXS Fragile X syndrome
hESC Human embryonic stem cell
hiPSC Human induced pluripotent stem cell
hPSC Human pluripotent stem cell
IGF-1 Insulin-like growth factor 1
Indel Insertion/deletion
iPSC Induced pluripotent stem cell
LTD Long-term depression
MEA Multielectrode array
mEPSC Miniature excitatory postsynaptic current
mGluR Metabotropic glutamate receptor
mIPSC Miniature inhibitory postsynaptic current
MRI Magnetic resonance imaging
NPC Neural progenitor cell
PCA Principal component analysis
PMDS Phelan-McDermid Syndrome
RTT Rett syndrome
TALEN Transcription activator-like effector nuclease
TS Timothy syndrome
UTR Untranslated region
ZFN Zinc finger nuclease
Introduction

Autism is a neurodevelopmental disorder defined by impairments in social interaction, deficits in verbal and nonverbal communication, and the display of stereotyped and repetitive behaviors. Comorbid symptoms include intellectual disability, seizures, anxiety, aggression, and sleep disorders. Typical autism is at the extreme end of the autism spectrum, which also includes Asperger’s syndrome, childhood disintegrative disorder and a set of disorders referred to as pervasive developmental disorder (PDD) not otherwise specified. The prevalence of autism spectrum disorder (ASD) is estimated to range between ~25 and ~110 in every 10,000, placing a substantial socioeconomic burden on families and society (Baird et al. 2006; Kogan et al. 2009). Although pharmacotherapy can manage ASD comorbidities, it does not address the core deficits. Current treatments are focusing on educational and behavioral interventions aimed at ameliorating maladaptive behaviors and promoting social interactions (Myers and Johnson 2007).

A prerequisite for the development of pharmacological agents targeting the core symptoms of ASD is a deeper understanding of the underlying pathophysiology. ASD has a strong genetic component and a small fraction of ASD cases is caused by defined genetic aberrations. Several mouse models of these syndromic forms of autism have provided insight into dysregulated pathways. The advent of somatic cell reprogramming now enables the study of ASD neurobiology using patient-derived cells. Ectopic expression of the four transcription factors Klf-4, Oct4, Sox2, and c-Myc induces reprogramming of somatic human cells to a pluripotent state (Takahashi et al. 2007; Takahashi and Yamanaka 2006). These human induced pluripotent stem cells (hiPSCs) retain the genetic composition of the cells they have been derived from (with the exception of stably integrated transgenes in the case of retro- or lentiviral approaches) and, owing to their pluripotent state, can be differentiated into cell types of all three germ layers. hiPSCs have characteristics similar to those of human embryonic stem cells (hESCs), derived from the inner cell mass of the embryonic blastocyst, and together hiPSC and hESCs are referred to as human pluripotent stem cells (hPSCs) in this review. Although reprogramming was initially established using dermal fibroblasts and using integrating viral vectors, recent advances allow derivation of hiPSCs from cell types accessible by less invasive methods, such as from keratinocytes (Aasen et al. 2008), peripheral blood T lymphocytes (Brown et al. 2010; Seki et al. 2011), and exfoliated renal epithelial cells found in urine samples (Zhou et al. 2011, 2012). In combination with efficient transgene-free reprogramming (Fusaki et al. 2009), these improvements facilitate the generation of hiPSCs from patients enrolled in clinical trials or studies.

A major limitation of hiPSC-based disease models is the fact that they necessitate the use of hiPSC lines generated from unaffected individuals as controls. Differences in genetic makeup are likely to contribute to interclonal variability between lines, further adding to differences in their properties caused by the reprogramming procedure itself (Hu et al. 2010). While in practice, these issues are addressed by generating multiple hiPSC lines from multiple patients and control individuals, the effect size of the phenotypes to be observed is usually unknown, making it impossible to estimate the number of cell lines required a priori. These barriers inherent in hiPSC-based disease modeling can be circumvented by targeted genetic manipulation of hPSCs. Sequence-specific designed zinc finger nucleases (ZFNs) or transcription activator-like effector nucleases (TALENs) can be used to generate a double strand break at a specific locus in the genome of hPSCs, allowing gene targeting via homology-directed repair or non-homologous end joining (Ding et al. 2013a; Lombardo et al. 2007). ZFNs and TALENs are now readily available (Kim et al. 2013; Xiao et al. 2013), enabling the disruption or mutation of virtually any gene. Recently developed advanced sequence-specific nuclease systems show improved targeting efficiency, making deletion even of large genomic segments possible, and thus open the door to model diseases caused by copy number variations (CNVs) (Cong et al. 2013; Ding et al. 2013b).

In this review, we provide a summary of the potential application of hPSCs for the generation of cellular models of ASD. We illustrate how insights from human genetic and transcriptome pathway studies as well as from mouse models inform the design of relevant hPSC models and discuss recent advances towards the generation of hPSC-derived neuronal populations that may enable modeling of human circuitry dysfunction in ASD.

Human genetics, mouse models, and pathway analyses: guiding the selection of appropriate hPSC models

Human genetics

ASD is highly heritable, with concordance rates in monozygotic twins estimated to be as high as 90% (Bailey et al. 1995; Steffenburg et al. 1989). Even though the causes of ASD are largely unknown, heritability provides a strong rationale for modeling ASD using genetically modified hPSCs and patient-derived hiPSCs, since neuronal populations derived from them will carry the causative genetic aberrations, which may lead to relevant neuronal dysfunction observable in vitro. Despite high heritability, the upper limit of the fraction of patients that harbor known genetic mutations likely causative for ASD is currently estimated at ~30–45% (Schaaf and Zoghbi 2011; Stein et al. 2013), indicating that the majority of genetic defects remain to be identified in idiopathic cases. Indeed, recent results from CNV (Gilman et al. 2011; Levy...
et al. 2011; Sanders et al. 2011) and exome sequencing (Lim et al. 2013; Michaelson et al. 2012; Yu et al. 2013) studies in large autism cohorts point to the involvement of hundreds of genes conferring ASD risk when mutated, disrupted, or duplicated. Overall, these genetic studies support a largely polygenic susceptibility model in which a minority of patients carries one of a few highly penetrant genetic aberrations, while the majority of patients harbor a small subset of hundreds of genetic aberrations that individually convey subthreshold risk (Neale et al. 2012). Models of genetically defined, syndromic forms of autism have provided critical insights into disease-causing mechanisms. They support the notion that despite the genetic heterogeneity, pathophysiological trajectories of ASD converge onto a limited number of affected pathways. Future research will address whether these emerging concepts will extend to idiopathic cases of ASD.

Many of these high-risk alleles are recurrent CNVs that affect large arrays of genes, while others are point mutations or small insertions and deletions (indels) which, although individually unique, collectively converge on a limited set of genes (Kelleher and Bear 2008). Intriguingly, most of these genes fall into two broad functional classes, namely, genes predominantly involved in regulating synapse structure and function (e.g., SHANK3,CNTNAP2, NRXN1, NLGN3/4X) and those involved in transcriptional and/or translational control (e.g., TSC1/2, MECP2, NF1, PTEN) (see review by Bourgeron et al. in this issue). The large numbers of genes affected in CNVs (which are readily detected using genome-wide microarrays and thus have been found more frequently than smaller indels or mutations, whose detection requires some form of targeted sequencing) present a challenge for the identification of causal genes. Network-based approaches for the analysis of genetic associations, using as input data genes affected by CNVs from ASD patients, may help address this challenge. Figure 1 shows a roadmap illustrating how insights from network-based analyses of genetic and transcriptomic data from ASD patients can inform the design of relevant ASD cellular models.

In one such network-based approach, termed NETBAG (Gilman et al. 2011), a large set of gene descriptors was first used to construct a background network of genes that are clustered based on their likelihood of contributing to a shared phenotype. When 433 candidate genes affected by 47 de novo CNVs from a large autism patient cohort were then mapped onto the network and interrogated for their capacity to support the preformed connections, several single genes within CNVs emerged as significantly associated (Gilman et al. 2011). HPSC lines with gene disruptions in these candidate genes, or in genes directly linked within the same cluster, will expand the range of human cellular ASD models and will enable direct probing of implicated pathways. In addition, such models will subsume genetic aberrations shared by several patients. Recent advances in genome editing technology now make it possible to construct such synthetic hPSC-based models, including those for which patient cells are not available for reprogramming (Fig. 1). Common molecular dysfunction observed in these models will also aid in patient stratification.

Despite the paucity of knowledge of “culprit” genes in CNVs, these disorders have advanced our understanding of autism pathophysiology. CNVs where deletions and reciprocal duplications cause largely overlapping clinical phenotypes, and those where the reciprocal change leads to opposing phenotypes, have been particularly instructive. For example, a CNV on 16p11.2 deleting ~600 kb and encompassing ~25 known coding genes is associated with autism, while duplication of the same region is associated with autism and schizophrenia (McCarthy et al. 2009). 16p11.2 deletions and duplications are also linked to macrocephaly and microcephaly, respectively (McCarthy et al. 2009). In contrast, deletion of a ~1.5-Mb chromosomal segment on 7q11.23 containing ~28 genes causes Williams syndrome (Merla et al. 2010). Individuals affected by this disorder have generally good verbal skills relative to their intelligence quotient and, strikingly, tend to be exceedingly sociable, approach strangers readily and hyperfocus on the eyes of others (Mervis and John 2010). In contrast, duplication of this region is associated with autism, mental retardation, language impairment, and epilepsy (Mervis and John 2010; Sanders et al. 2011). Lastly, loss of a ~5-Mb region on 15q11-13, harboring 10–15 coding genes, on the maternal chromosome causes Angelman syndrome (Pembrey et al. 1989), characterized by developmental delay, speech impairment, ataxia, and a unique combination of behavioral phenotypes that include a generally happy disposition, frequent smiling and laughing, and excitability (Williams et al. 2006). In contrast, individuals with duplications or triplications encompassing this region are autistic, with penetrance of ASD phenotypes correlating with CNV dosage (Hogart et al. 2010). Thus, syndromes related to one another by reciprocal CNVs illustrate that opposing gene dosage can lead to either converging or opposing clinical phenotypes. The example of the 16p11.2 CNV suggests that the autism phenotype may not be linked to its specific copy number (and, consequently, to gene dosage). Analyses of CNVs in rodents and humans have shown that, instead, it may be the structural change in the genome caused by the CNV that contributes to the phenotype. Support for this hypothesis comes from rodent studies of CNV-dependent dosage sensitivity of gene expression. Here, an only modest correlation between copy number and gene dosage was observed in general, with particularly low correlation in the brain (Henrichsen et al. 2009a,b; Reymond et al. 2007). These observations have major implications for modeling functional consequences of CNVs in mouse models (see below).

Nevertheless, hiPSC models of these syndromes may help understand how and where on the pathophysiological
trajectory these reciprocal CNV syndromes converge or diverge. Although knowledge of the critical genes in these CNVs is still limited, experiments in zebrafish have linked the head size phenotype in 16p11.2 CNVs to dysregulation of the neural progenitor cell (NPC) proliferation gene \textit{KCTD13}, which codes for a protein that interacts with the proliferating cell nuclear antigen (Golzio et al. 2012). The finding that a subset of Angelman patients harbor point mutations in \textit{UBE3A} within the 15q11-13CNV strongly suggests that dysfunction of this gene, coding for an E3 ubiquitin ligase, is primarily responsible for the phenotype (Kishino et al. 1997). Targeted genetic manipulation of these candidate genes in hPSCs will help identify the molecular underpinnings of ASD and may ultimately serve as cellular models (Fig. 1).

Further advances, alongside reductions in the costs associated with deep sequencing, will make whole genome sequencing of large patient cohorts feasible in the near future. These studies will undoubtedly reveal additional small risk-conferring genetic defects (indels and point mutations) outside of the coding regions of known genes, particularly in promoter and enhancer regions, where variation in human populations is higher than in coding regions, and within long non-coding ribonucleic acids (RNAs), which have recently come into focus as important players in neurogenesis and neuropsychiatric disorders (Lin et al. 2011). These advances will likely expand the set of informative genotypes, which can be exploited to model ASD with human hPSCs.

Insights from transcriptome analyses in human brain postmortem brain

Volumetric magnetic resonance imaging (MRI) studies, combined with structural analyses of postmortem brains of ASD patients, have identified associated neuroanatomical and cellular aberrations. Overall, these findings point to increased brain growth beginning in the first postnatal year, persisting at least into early childhood (Courchesne et al. 2007). More detailed analyses have revealed changes in neuronal size, number, and density, as well as defects in neuronal organization in frontal and temporal cortex, anterior cingulate, amygdala, and cerebellum (Amaral et al. 2008; Schumann and Nordahl 2011). Although these alterations are likely due to defects in regulation of neuronal differentiation, proliferation, and migration, their molecular underpinnings remain elusive. Transcriptome analyses of these brain regions in large cohorts of ASD patients may help identify commonly dysregulated
pathways converging from the heterogeneous genetic background of the disorder (Fig. 1). Such studies, however, have only recently begun to emerge (Chow et al. 2012; Voineagu et al. 2011).

In a seminal paper, Geschwind and colleagues analyzed the transcriptomes of frontal and temporal cortex and cerebellum from 19 postmortem brains from idiopathic cases of ASD and from 17 control individuals (Voineagu et al. 2011). An analysis approach based on identification of gene coexpression networks revealed that the most significantly ASD-correlated module of functionally related genes was enriched for genes involved in synaptic function, as well as for known autism susceptibility genes. Thus, in addition to confirming involvement of synaptic dysfunction in ASD, these findings strongly suggest that transcriptomic approaches can identify molecular commonalities in ASD brains, and we can now address whether hiPSC-derived neurons can identify these molecular signatures. The dominant module was anchored by A2BP1, the gene coding for the neuron-selective splicing factor RBFOX1, thus implicating splicing dysregulation in ASD (Fogel et al. 2012). Since A2BP1 itself had previously been identified as an autism susceptibility gene in humans (Martin et al. 2007), these results provide a strong rationale for creating hPSC-based ASD models with defects in this gene. Intriguingly, the study also showed that differences in gene expression patterns between frontal and temporal cortex were attenuated in ASD brains, suggesting defects in cortical specification, patterning, and/or organization (Voineagu et al. 2011). Thus, similar to network-based analyses of de novo CNVs in ASD patients, postmortem transcriptome studies pinpoint pathways commonly dysregulated in ASD (Fig. 1). Transcriptome profiles will also help validate and benchmark hPSC-based models—either obtained by cellular reprogramming of patient-derived cells or generated by genome editing in normal hPSCs—of critical genes within these pathways and will be crucial to test the relevance of pathways implicated in ASD pathophysiology.

Mouse models

Mouse models of genetically defined, syndromic forms of ASD phenocopy core autism deficits and have provided critical insight into pathophysiological mechanisms. In mouse models of fragile X syndrome, Rett syndrome and tuberous sclerosis complex, reversal of autism phenotypes of autism.

One of the central hypotheses for molecular mechanisms shared among different forms of ASDs is aberrant regulation of translation causing increased protein synthesis (Kelleher and Bear 2008). For example, a positron emission spectroscopy imaging study of children with pervasive
developmental disorder showed a positive correlation of autism index scores with protein synthesis rates in language brain regions (Shandal et al. 2011). In addition, translation is the final common mechanism regulated by the fragile X mental retardation protein (FMRP) and mTOR pathways, both strongly linked to autism (see below). Transgenic mice mildly overexpressing eIF4E, the rate-limiting factor in the assembly of the translation initiation complex, show autistic-like behaviors, increased miniature excitatory postsynaptic current (mEPSC) frequency and amplitude and enhanced hippocampal metabotropic glutamate receptor (mGluR)-mediated long-term depression (LTD) (Santini et al. 2013). Similarly, mice null for one of the three eIF4E-binding proteins (Eif4ebp2 knockout), which sequester eIF4E, display autism-related deficits and an increased ratio of excitatory to inhibitory synaptic inputs (Gkogkas et al. 2013). Strikingly, among 24 autism-relevant proteins examined in both models, only neuroligins (Nlgn1-4) showed enhanced translation, indicating strong selectivity in the genes affected by the loss of eIF4E-dependent translational control (Gkogkas et al. 2013). The ASD-like phenotypes could be reversed by Nlgn1 knockdown and by intracerebroventricular infusion of the small-molecule inhibitor of cap-dependent translation, 4-EGI (Santini et al. 2013). Translation dysfunction thus links upstream signaling defects to downstream synaptic dysfunction, strongly impacting translation hyperfunction as a defect common in both syndromic and idiopathic ASD. The advent of genome editing now makes it possible to similarly create hPSCs with translation dysregulation, paving the road towards human cellular models of idiopathic ASD (Fig. 1).

Existing hiPSC models of ASD: insights from genetically defined cases

Identification of phenotypes in hiPSC-based models of ASD has been achieved in four syndromic forms of ASD with known single gene defects: Rett syndrome (RTT), Phelan-McDermid Syndrome (PMDS), Timothy syndrome (TS), and fragile X syndrome (FXS). These studies have paved the way for the use of hiPSC-derived neuronal populations as cellular models of ASD. Electrophysiological analyses of hiPSC-derived neurons have demonstrated fundamental neuronal firing properties and spontaneous inhibitory and excitatory currents, demonstrating synaptic connectivity. Although the neurons of the middle to upper cortical layers of the human cortex provide the intracortical circuitry that is among those thought to be perturbed in ASD, these types of neurons are not generated in basic hPSC differentiation protocols. Nevertheless, since more recent differentiation protocols have begun to address neuronal region specificity, these hPSC lines can now be used for more detailed analyses of neuronal function at the network and circuit levels (see below).

Rett syndrome

RTT is a severe X-linked neurodevelopmental disorder that occurs in approximately 1 in 10,000 female births and confers a highly increased risk of developing autism-like behaviors and seizures (Chahour and Zoghbi 2007). RTT was the first PDD for which a genetic cause could be identified (Amir et al. 1999) and, more than 10 years later, the first PDD for which hiPSC-based models were established (Marchetto et al. 2010). Thus, animal and cellular models of RTT have become prototypical for understanding the molecular pathophysiology of RTT and have nurtured the hope that insights gained from them may extend to other ASDs. Typical RTT is caused by defects in the gene encoding the transcriptional regulator, methyl CpG binding protein 2 (MECP2), involved in transcriptional regulation via alteration of chromatin structure (Baker et al. 2013). Clinical manifestations of RTT include severe intellectual disability, loss of language, stereotypic hand wringing, and motor abnormalities.

Even prior to the identification of MECP2 as the gene affected in RTT, morphological alterations to neuronal structure had been observed in human postmortem tissue, notably small neuronal size and reduced dendritic arbors in specific cortical areas and layers (Armstrong et al. 1995, 1998). Strikingly, these abnormalities were subsequently found in mice mutant for Mecp2 (Chen et al. 2001; Kishi and Macklis 2004). Although an in vitro approach using cultured dissociated neurons from these mice did not find any effects on dendritic branching or complexity (Chao et al. 2007), hiPSC-derived neurons from RTT patients and hESC-derived MECP2 hemizygous neurons, created by genome editing, also have significantly reduced cell soma size and dendritic branching (Cheung et al. 2011; Marchetto et al. 2010). MECP2 mutant neurons showed a global reduction in transcriptional output (Yazdani et al. 2012), with levels of actively transcribed genes being particularly affected (Li et al. 2013). Synaptic deficits have been observed in models spanning from human RTT hiPSC- (Marchetto et al. 2010) and hESC-derived neurons (Li et al. 2013), iPSC-derived neurons from mice mutant for Mecp2 and mouse mutant neuronal cultures (Chao et al. 2007), in vitro acute brain slices from mutant mice (Dani et al. 2005), and even, at least to a limited extent, in vivo data from mutant mice (Chao et al. 2007). In the aggregate, these data suggest that, in the absence of MECP2, neurons fail to maintain gene expression at levels critical for neuron-specific functions, including activity-dependent transcription (Li et al. 2013).

Electrophysiological analysis of spontaneous miniature excitatory and inhibitory postsynaptic currents (mEPSCs and mIPSCs) can impart information on the number and type of synaptic connections in a neural network. HiPSC-derived neurons from patients with RTT show reduced frequency and amplitude of mEPSCs and, to a lesser extent, mIPSCs
Phelan-McDermid Syndrome

Phelan-McDermid Syndrome (PMDS) is a neurodevelopmental disorder caused by deletion of the SHANK3 gene on the terminal end of chromosome 22 (also known as 22q13 deletion syndrome). It causes a wide range of symptoms including seizures, intellectual disability and sleep disorders, as well as being strongly associated with ASD (Phelan and McDermid 2012). Recently, hiPSC-derived neurons have been generated from PMDS patients and were found to have significant deficits in excitatory synaptic transmission. Not only were these deficits resuable by expression of SHANK3 itself, but they were also corrected by pharmacological treatment with IGF-1 (Shcheglovitov et al. 2013). These results add weight to the concept that synaptic abnormalities may be treatable by pharmacotherapy, and indeed that where diverse genetic defects converge on similar synaptic dysfunction there may be commonalities in treatment options.

Timothy syndrome

Timothy syndrome (TS) is an extremely rare autosomal dominant multisystem disorder caused by mutations in CACNA1C, coding for the alpha-1 (voltage sensor and pore-forming) subunit of the L-type voltage-gated calcium channel Cav1.2 (Splawski et al. 2004, 2005). A member of the long QT family of syndromes, TS causes prolongation of the cardiac QT interval in affected individuals. Patients with classic (type 1) TS harbor a recurrent de novo missense mutation (Gly→Arg) at position 406 in exon 8A. Approximately 25 patients with classic TS have been described, while two patients with a more severe variant of TS (atypical or type 2 TS) have a Gly→Arg mutation in the more highly expressed alternative exon 8 (Splawski et al. 2006). As CACNA1C is expressed in multiple tissues, mutation causes dysfunction in multiple organs, including syndactyly (in 100% of type 1 cases), congenital heart disease (61%), cardiac arrhythmia (84%), immune deficiency (57%), and autism (75%). Type 2 TS is characterized by the presence of extreme prolongation of the QT but absence of syndactyly. TS patients die at an average of 2.5 years, and the leading cause of death is ventricular tachycardia. Thus, as is common with syndromic forms of autism, morbidity caused by autistic behaviors is a relatively minor aspect within a large spectrum of severe clinical manifestations (Splawski et al. 2006).

Dolmetsch and colleagues generated cortical-enriched neuronal populations differentiated from several hiPSC lines derived from two type-1 TS patients and showed that mutant neurons exhibit action potentials wider than those of control cells, in agreement with a loss of Cav1.2 channel inactivation (Pasca et al. 2011). Calcium imaging in cortical progenitors and in synapsin-positive mature neurons revealed an increase in the sustained intracellular calcium rise following membrane depolarization, strongly suggesting that TS NPCs and neurons have deficiencies in calcium signaling, with concomitant changes in activity-dependent gene expression. Remarkably, TS neuronal cultures contained more cells expressing tyrosine hydroxylase and produced more norepinephrine and dopamine, a phenotype also observed in the valproic acid model of ASD (D’Souza et al. 2009). Unexpectedly, of those neurons in the culture that expressed lower layer cortical markers, TS neurons also contained fewer cells
expressing SATB2, critical for formation of corpus callosum projection neurons. This observation was confirmed in a transgenic mouse model expressing the mutant channel under the forebrain-specific FOXG1 promoter (Pasca et al. 2011). Thus, these results indicate that neuronal specification deficits caused by TS mutations can be recapitulated in both hiPSC-derived neurons and mouse models. The study also underscores the fact that differentiation of hiPSC-derived neurons of appropriate subtypes is critical to reveal alterations in neuronal specification, as such changes may contribute to neural circuitry dysfunction in ASD patients.

A mouse model of type 2 TS showed robust behavioral phenotypes reflecting the three core traits of autism, including restricted, repetitive, and perseverative behaviors, reduced socialization with other animals, and altered ultrasonic vocalization (Bader et al. 2011). Although analyses of alterations in neuron morphology and function or brain circuitry that may underlie these behaviors were not reported in this study, a similar mouse model was recently constructed and characterized by Dolmetsch and colleagues (Krey et al. 2013). CaV1.2 couples changes in membrane potential to dendritic arborization, possibly by recruiting small GTP-binding protein family members, which in turn regulate signaling controlling arborization. Frontal cortex layer 2/3 pyramidal neurons from TS mice showed a decrease in total basal dendritic length and the number of dendritic branches by postnatal day 14, indicating a net reduction in basal dendritic complexity in an early postnatal phase. Importantly, these effects on activity-dependent dendritic refinement were also observed in vitro, using both primary rat cortical neurons and several hiPSC neuronal lines from the two type-1 TS patients. Detailed analyses revealed that mutant CaV1.2 channels are deficient in recruiting sufficient levels of the small GTP-binding protein Gem, thus causing excessive activation of RhoA and activity-dependent dendritic retraction independent of calcium signaling (Krey et al. 2013). These insights highlight that hiPSC modeling of ASD requires assays tailored to the known function of the affected gene to unravel pathophysiological mechanisms. The study also illustrates the value of a complementary approach that includes evidence from rodent and human cellular models and in vivo rodent data.

Fragile X syndrome

Fragile X syndrome (FXS) is an X-linked dominant disorder and the most common form of inherited intellectual disability, affecting ~1 in 4,000 newborns (Coffee et al. 2009). Clinically, FXS is characterized by mild to severe cognitive deficits and behavioral abnormalities that include hyperactivity and autism-like behaviors (Gallagher and Hallahan 2012). The syndrome is caused by the absence of expression of the fragile X mental retardation 1 (FMR1) gene, coding for the RNA binding protein FMRP. Typically, loss of FMRP in FXS is caused by abnormal CGG triplet repeat expansion in the 5′ untranslated region (5′ UTR) of the gene, leading to developmentally controlled CpG methylation in the promoter and 5′ UTR region and thus resulting in gene silencing (Feng et al. 1995). Repeat numbers >200 lead to complete silencing in neurons and cause FXS, while repeat expansions in the premutation range (55–200 repeats) are associated with upregulation of FMR1 expression and cause the late onset neurodegenerative disease, fragile X associated tremor ataxia syndrome, probably via a toxic gain of function of the CGG-rich RNA transcript (Gallagher and Hallahan 2012).

Although a mouse model carrying ~230 repeats did not recapitulate the abnormal methylation of the promoter and 5′ UTR methylation seen in humans (Brouwer et al. 2008), Fmr1 knockout mice display many features of FXS, including autistic behaviors (Consortium TD-BFX 1994). FMRP, a suppressor of messenger RNA translation, is required for activity-dependent regulation of synaptic protein synthesis, which is stimulated by activation of group 1 mGluRs, including mGluR5. Since many of the long-term consequences of mGluR5-mediated signaling, including LTD, are dependent on protein translation, it has been hypothesized that mGluR5 inhibition could counteract neuronal dysfunction in FXS (Bear et al. 2004). Indeed, strong support for the “mGluR5 hypothesis for FXS” theory comes from several recent studies in which pharmacological or genetic intervention aimed at reducing mGluR5-dependent signaling prevented and/or reverted FXS phenotypes (Dolen et al. 2007; Michalon et al. 2012; Silberman et al. 2012).

Human ESCs derived from FXS-affected blastocyst-stage embryos express FMRP and gene silencing via promoter methylation occurs only upon differentiation (Eiges et al. 2007). In contrast, hiPSCs derived from fibroblasts of affected patients showed deoxyribonucleic acid (DNA) methylation and transcriptional silencing even in the pluripotent stage, indicating that somatic reprogramming did not erase these chromatin marks (Ürbach et al. 2010). Thus, although these hiPSCs do not recapitulate developmentally regulated FMR1 silencing, they may nevertheless represent a useful model system for screening of compounds capable of reactivating the gene (Bar-Nur et al. 2012). Differentiation of hiPSCs towards neurons showed reduced neurite numbers and neurite lengths (Sheridan et al. 2011), phenotypes that resemble those seen in the Fmr1 knockout mouse (Braun and Segal 2000; Luo et al. 2010) and in human FXS postmortem tissue (Castren et al. 2005). In the future, it will be important to address whether FXS hiPSC-derived neurons display exaggerated mGluR5 signaling and defects in LTD and, if so, whether these phenotypes can be reverted with mGluR5 inhibitors.
ASD modeling in a dish: towards neuronal circuits

Efficient neural specification using defined morphogens

A major breakthrough was the development of protocols that robustly, reproducibly, and efficiently convert hPSCs into neural ectoderm tissue. Noggin, a bone morphogenetic protein inhibitor, had previously been demonstrated to have robust neural-inducing properties (Pera et al. 2004). Similarly, the small molecule SB431542, which inhibits the Lefty/activin/transforming growth factor beta pathways by blocking phosphorylation of the ALK4, ALK5, and ALK7 receptors, enhances neural induction in hPSCs (Patani et al. 2009). The combination of noggin and SB431542 (dual SMAD inhibition), then enabled rapid and uniform neural induction of hPSCs under adherent culture conditions, and allowed the derivation of relevant neuronal subtypes in a shorter time (~19 days) (Chambers et al. 2009). Others have reported similarly efficient neural induction in both hESCs and hiPSCs with the small molecule dorsomorphin in place of noggin (Kim et al. 2010). Although the dual SMAD inhibition protocol in its original form gives rise to a heterogeneous population of neuronal cell types (both telencephalic and diencephalic), recent modifications have enabled the derivation of more specialized neuronal precursor and mature neuron populations, including floor plate precursors, midbrain dopaminergic neurons, and cortical neurons (Fasano et al. 2010; Kriks et al. 2011; Shi et al. 2012c).

Accelerating differentiation towards homogeneous neuronal populations

HPSC-derived neurons presently require long maturation times to reach a level of neuronal connectivity that allows the study of synaptic physiology (60–120 days). In order to facilitate adaptation of these cultures for drug screening, future improvements will therefore have to focus on assessing synaptic physiology and accelerating neuronal maturation. For example, in several studies, electrophysiologically active human neurons initially exhibit immature properties, including smaller, slower action potentials and the inability to fire repetitively, in contrast to more mature neurons (Shi et al. 2012c). Thus, baseline intrinsic membrane properties (e.g., resting membrane potential, input resistance) and action potential firing properties (e.g., threshold, amplitude, rise time), as well as percentages of neurons with differing firing rates, define the degree of differentiation, and should be systematically monitored while optimizing neuronal protocols to model synaptic dysfunction.

Modeling neuronal circuitry deficits and properties of specific synapses, such as cortico-striatal and excitatory/inhibitory connections, requires cultures that are highly enriched for specific neuronal subpopulations. Fluorescence-activated cell sorting (FACS) has been used to isolate hiPSC-derived neural crest cells (Lee et al. 2009), NPCs, and even mature neurons (Israel et al. 2012; Yuan et al. 2011). The use of specific combinations of neuronal cell surface markers may thus allow the prospective isolation of additional neuronal lineages. Significantly, in their study of hiPSC-derived neurons from patients with Alzheimer’s disease, Goldstein and colleagues used FACS-based purification to reduce the variability in the efficiency of neuronal differentiation between hiPSC lines, providing increased power to identify disease-related changes (Israel et al. 2012). The identification of additional cell surface neuronal markers of specific subtypes, particularly middle and upper layer cortical neurons and inhibitory neurons, will facilitate progress towards pure populations of specific cortical subpopulations. Although not explored in hPSCs to date, reporter constructs expressing green fluorescent protein, under the control of a lineage-specific promoter, may be generated by genome editing, allowing the enrichment of additional neuronal lineages, including those for which cell surface markers are not known.

Figure 2 shows that using proliferating hPSC-derived NPCs as a starting point for differentiation dramatically
shortens the time required to obtain mature neurons with gene expression profiles approximating that of human brain. Additional modulation of the composition of the differentiation factor cocktail can modestly accelerate maturation (Fig. 2).

One exciting recent approach towards further speeding up differentiation and generating homogenous cell populations is direct lineage conversion from non-neuronal cells by the forced expression of neuronal transcription regulators (Pang et al. 2011; Vierbuchen et al. 2010). Overexpression of the forebrain transcription regulators ASCL1, BRN2, ZIC1, MYT1L, and OLIG2 directly converts human fibroblasts into neurons with forebrain glutamatergic properties within 21 days (Qiang et al. 2011). However, fibroblasts have limited proliferative capacity in vitro, thus limiting the number of cells available from a patient biopsy. Dopaminergic neurons (Sanchez-Danes et al. 2012a) and motor neurons (Hester et al. 2011) have been generated from hPSCs and NPCs by combining different sets of transcription factors, indicating that subtype-specific neuronal differentiation can be achieved. Such "induced neurons" from Alzheimer's and Parkinson's patients have shown disease-relevant cellular phenotypes (Qiang et al. 2011; Sanchez-Danes et al. 2012a,b). Although this approach may help reduce some of the variability in cellular homogeneity associated with current morphogen-based procedures, it is clear that differentiation by forced transgene expression may not allow the observation of subtle defects in neuronal specification and maturation, such as those observed in TS neurons (Pasca et al. 2011). Thus, although the usefulness of induced neurons in modeling the molecular and cellular defects of neurodegenerative diseases has been demonstrated, it remains to be seen whether they can also generate neurons capable of supporting a neuronal network relevant to neurodevelopmental disorders.

Cortical specification

Relatively simple differentiation protocols, such as the one used to generate the neurons analyzed in Fig. 2, can generate neurons that approximate the gene expression pattern of human cortex. However, these neurons do not recapitulate the elaborate cortical layer-specific specification seen in vivo. Particularly relevant to ASD disease modeling, inclusion of retinoic acid in the dual SMAD inhibition procedure leads to cortical neuron identity, based on the appearance of cortical projection markers in precursors, which subsequently give rise to upper and lower layer cortical projection neurons (Shi et al. 2012c). Remarkably, all classes of cortical projection neurons found in vivo are generated and the temporal order of their emergence recapitulates in vivo cortex development. Importantly, between 60 and 120 days after the onset of neuronal derivation, the retinoic acid/dual SMAD inhibition protocol yields mature cortical neurons with appropriate electrophysiological properties and functional synapses (Michaelson et al. 2012; Shi et al. 2012a,b). Prolonged exposure to noggin resulted in robust induction of telencephalic/cortical genes, while shorter treatments yield a mixture of diencephalon and telencephalon induction, but the in vitro temporal sequence of generation of cortical neuron types again followed in vivo development. When cortical pyramidal neurons generated in vitro were transplanted into mouse neonatal brain, they developed axonal projections and dendritic morphology which corresponded to endogenous cortical neurons. Thus, the fact that neurons generated in vitro develop properties of human cortical neurons in vivo offers an unprecedented opportunity to study ASD both in vitro and in animal xenograft models. These recent studies bring hope that specific cortical neuronal circuitry can be modeled using hPSCs relevant to ASD. Given that the expanded upper layers of the cortex are a cardinal feature of the human cortex, the specific generation of these neurons from hPSCs has potential for revealing specific aspects of cortical circuitry dysfunction in ASD.
Neuronal circuits

MRI studies and postmortem analyses of autistic individuals have consistently demonstrated anatomical abnormalities in several brain regions (including cortical frontal lobe, striatum, amygdala, and cerebellum), while functional MRI studies found differences in the activity of specific brain areas during cognitive tasks when compared to neurotypical controls (Amaral et al. 2008; Schumann and Nordahl 2011). Thus, meaningful relationships will need to be established between the cellular, molecular, and network-based properties of hPSC-based models of ASD, on the one hand, and the anatomical and functional endophenotypes of ASD patients’ brains, on the other. In cellular models of ASD, disease-relevant dysfunction may reveal itself at distinct levels of functional complexity within the cell population (Fig. 3).

The different phenotypic trajectories of different hPSC-based ASD models likely converge at several levels of functional complexity as well, illustrating the requirement for mature, synaptically connected neurons capable of sustaining a neuronal network (Fig. 3). Aberrant neuronal network activity is strongly implicated as directly underlying many forms of brain dysfunction, including ASD. In particular, disruptions in the balance between excitatory/inhibitory (E/I) inputs have been observed in both ASD patients and mouse models of the disorder, pointing towards neural circuit dysfunction as the convergence point of pathophysiological trajectories that originate from diverse etiologies (Penzes et al. 2013). For example, Cntnap2 knockout mice, lacking a gene associated with ASD, show reduced numbers of GABAergic interneurons and decreased neuronal synchrony in the cortex (Penagarikano et al. 2011). Moreover, ASD mouse models engineered to display disinhibition of eIF4E-dependent control of protein synthesis have a decreased ratio between inhibitory and excitatory synaptic inputs (Gkogkas et al. 2013; Santini et al. 2013). Thus, the relevance of hPSC-based cellular models for ASD ultimately hinges on the successful in vitro generation of functional neuronal networks, characterized by synaptically connected excitatory and inhibitory neurons at physiologically relevant proportions. Given the different developmental origins and lineages of excitatory cortical pyramidal neurons and inhibitory
neurons on MEAs (Fig. 3) or by measuring intracellular calcium transients using Ca\(^{2+}\)-sensitive dyes applied to neuronal cultures. MEAs allow repeated measurements of differentiation cultures over time, allowing investigation of maturation kinetics. In contrast to electrophysiological approaches, calcium imaging is amenable to high-throughput assay formats, allowing the development of drug screens using hPSC-based cellular models of ASD. When combined with subsequent immunocytochemistry, specific neuronal subtypes (such as excitatory vs. inhibitory neurons) or subnetworks of cells that show aberrations in their network behavior can be identified. Owing to these advantages, it is therefore likely that measurement of network properties by calcium imaging will be one of the key technologies in translational ASD research.

**Outlook**

The key to understanding the pathophysiology of ASD and the development of therapeutics is the development of robust disease-relevant cellular models. These efforts comprise (1) establishing hPSCs from biopsy material of ASD patients with diverse genetic etiologies and from neurotypical control individuals, (2) genetic engineering of normal hPSCs to generate matched isogenic sets of lines with targeted ASD-relevant genetic defects, (3) the development of robust, efficient and relevant neuronal differentiation protocols, and (4) the definition of ASD-related cellular phenotypes upon which corresponding cellular assays can be built. The design of these models and assays will need to be continuously informed and guided by insights from mouse models and from genetic, molecular, and functional studies in the ASD population.

Given the diverse genetic and clinical landscape of ASD patients, it is evident that a single cellular model will not recapitulate all aspects of ASD pathology from all ASD patients. Nevertheless, our increased appreciation that different pathophysiological trajectories may converge on a limited set of molecular pathways fuels the hope that a limited number of cellular models may address a majority of relevant phenotypes. Major inroads into all these areas have been built in the recent past; the time is now ripe for hPSCs models to be implemented in ASD discovery research.

**Acknowledgments** The authors have received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115300, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in-kind contribution. S.A. was supported by a Roche Postdoctoral Fellowship (RPF). We thank Veronica Costa for providing the cell cultures and Fred Knollach for recording the multi-electrode array data used for Fig. 3.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

**References**

Aasen T, Raya A, Barrero MJ, Garreta E, Consiglio A, Gonzalez F, Vassena R, Blic B, Pekarik V, Tiscornia G, Edel M, Boue S, Izpisua Belmonte JC (2008) Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 26:1276–1284

Amaral DG, Schumann CM, Nordahl CW (2008) Neuroanatomy of autism. Trends Neurosci 31:137–145

Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23:185–188

Armstrong D, Dunn JK, Antalffy B, Trivedi R (1995) Selective dendritic alterations in the cortex of Rett syndrome. J Neuropathol Exp Neurol 54:195–201

Armstrong DD, Dunn K, Antalffy B (1998) Decreased dendritic branching in frontal, motor and limbic cortex in Rett syndrome compared with trisomy 21. J Neuropathol Exp Neurol 57:1013–1017

Bader PL, Faizi M, Kim LH, Owen SF, Tadross MR, Alfa RW, Bett GC, Tsien RW, Rasmussen RL, Shamloo M (2011) Mouse model of Timothy syndrome recapitulates triad of autistic traits. Proc Natl Acad Sci U S A 108:15432–15437

Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E, Rutter M (1995) Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 25:63–77

Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, Charman T (2006) Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 368:210–215
Baker SA, Chen L, Wilkins AD, Yu P, Lichtarge O, Zoghbi HY (2013) An AT-hook domain in MeCP2 determines the clinical course of Rett syndrome and related disorders. Cell 152:984–996

Bar-Nur O, Caspi I, Benvenisty N (2012) Molecular analysis of FMR1 reactivation in fragile-X induced pluripotent stem cells and their neuronal derivatives. J Mol Cell Biol 4:180–183

Bear MF, Huber KM, Warren ST (2004) The mGlur theory of fragile X mental retardation. Trends Neurosci 27:370–377

Braun K, Segal M (2000) FMRP involvement in formation of synapses among cultured hippocampal neurons. Cereb Cortex 10:1045–1052

Breitbart IJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sanger S, Li Y, Mu Y, Chen G, Yu D, McCarthy S, Sebat J, Gage FH (2011) Modelling schizophrenia using human induced pluripotent stem cells. Nature 473:221–225

Brouwer JR, Huizker K, Severijnen LA, Hukema RK, Berman RF, Oostra BA, Willemsen R (2008) CGG-repeat length and neuropathological and molecular correlates in a mouse model for fragile X-associated tremor/ataxia syndrome. J Neurochem 107:1671–1682

Brown ME, Rondon E, Rajesh D, Mack A, Lewis R, Feng X, Zitur LJ, Learish RD, Nuwayser EF (2010) Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes. PLoS One 5:e11373

Castren M, Tervonen T, Karkkainen V, Heinonen S, Castren E, Larsson K, Brown ME, Rondon E, Rajesh D, Mack A, Lewis R, Feng X, Zitur LJ, Learish RD, Nuwayser EF (2010) Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes. PLoS One 5:e11373

Chahroul M, Zoghbi HY (2007) The story of Rett syndrome: from clinical to neurobiology. Neuron 56:422–437

Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelan M, Studer L (2009) Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 27:275–280

Chao HT, Zoghbi HY, Rosenmund C (2007) MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number. Neuron 56:58–65

Chen RZ, Akbarian S, Tudor M, Jaenisch R (2001) Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 27:327–331

Cheung AY, Horvath LM, Grafodatskaya D, Pasceri P, Weksberg R, Castren M, Tervonen T, Karkkainen V, Heinonen S, Castren E, Larsson K, Brown ME, Rondon E, Rajesh D, Mack A, Lewis R, Feng X, Zitur LJ, Learish RD, Nuwayser EF (2010) Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes. PLoS One 5:e11373

Coffee B, Keith K, Albizua I, Malone T, Mowrey J, Sherman SL, Barnes CC, Li HR, Weiss L, Cheung AY, Horvath LM, Grafodatskaya D, Pasceri P, Weksberg R, Castren M, Tervonen T, Karkkainen V, Heinonen S, Castren E, Larsson K, Brown ME, Rondon E, Rajesh D, Mack A, Lewis R, Feng X, Zitur LJ, Learish RD, Nuwayser EF (2010) Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes. PLoS One 5:e11373

Ding Q, Lee YK, Schaefer EA, Peters DT, Veres A, Kim K, Kuperwasser Courchesne E, Pierce K, Schumann CM, Redcay E, Buckwalter JA, Consortium TD-BFX (1994) Fmr1 knockout mice: a model to study mental retardation. Trends Neurosci 27:370–377

Dolens G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, Bear MF (2007) Correction of fragile X syndrome in mice. Neuron 56:955–962

Dragunow M (2008) The adult human brain in preclinical drug development. Nat Rev Drug Disc 7:659–666

DSouza A, Onen E, Patel P, La Gamma EF, Nankova BB (2009) Valproic acid regulates catecholaminergic pathways by concentration-dependent threshold effects on TH mRNA synthesis and degradation. Brain Res 1247:1–10

Eiges R, Urbach A, Malcov M, Frumkin T, Schwartz T, Amit A, Yaron Y, Eden A, Yanuka O, Benvenisty N, Ben-Yosef D (2007) Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell 1:568–577

Farra N, Zhang WB, Pascrei P, Eubanks JH, Salter MW, Ellis J (2012) Rett syndrome induced pluripotent stem cell-derived neurons reveal novel neurophysiological alterations. Mol Psychiatry 17:1261–1271

Fasano CA, Chambers SM, Lee G, Tomishima MJ, Studer L (2010) Efficient derivation of functional floor plate tissue from human embryonic stem cells. Cell Stem Cell 6:336–347

Feng Y, Zhang F, Lokey K, Chastain JL, Lakkis L, Eberhart D, Warren ST (1995) Translational suppression by trinucleotide repeat expansion at FMR1. Science 268:731–734

Fogel BL, Wexler E, Wahnich A, Friedrich T, Vijayendran C, Gao F, Parishak N, Konopka G, Geschwind DH (2012) Rbfox1 regulates both splicing and transcriptional networks in human neuronal development. Hum Mol Genet 21:4171–4186

Fukasi N, Ban H, Nishiyama A, Saeki K, Hasegawa M (2009) Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci 85:348–362

Gallagher A, Hallahan B (2012) Fragile X-associated disorders: a clinical overview. J Neurol 259:401–413

Geiman LT, Stoilov P, Maguire J, Dumanian A, Lin CH, Shiue L, Ares M Jr, Mody I, Black DL (2011) The splicing regulator Rbfox1 (A2BP1) controls neuronal excitation in the mammalian brain. Nat Genet 43:706–711

Gilman SR, Jossifov I, Levy D, Ronemus M, Wigler M, Vitkup D (2011) Rare de novo variants associated with autism imply a large functional network of genes involved in formation and function of synapses. Neuron 70:898–907

Girirajan S, Rosenfeld JA, Cooper GM, Antonacci F, Siswara P, Itsara A, Vives L, Walsh T, McCarthy SE, Baker C, Mefford HC, Kidd JM, Browning SR, Browning BL, Dickel DE, Levy DL, Ballif BC, Platky K, Farber DM, Gowans GC, Wetherbee JJ, Asamoah A, Weaver DD, Mark PR, Dickerson J, Garg BP, Ellingwood SA, Smith R, Banks VC, Smith W, McDonald MT, Hoo JJ, French BN, Hudson C, Johnson JP, Ozmor RE, Moeschler JB, Surti U, Escobar LF, El-Khechen D, Gorski JL, Kussmann J, Salbert B, Lacassie Y, Biser A, McDonald-McGinn DM, Zackai EH, Deardorff MA, Shaikh TH, Haan E, Friend KL, Fichera M, Romano C, Gezz J, Dellei SE, Leat J, King MC, Shaffer LG, Eichler EE (2010) A recurrent 16p12.1 microdeletion supports a two-hit model for severe developmental delay. Nat Genet 42:203–209
Gkogkas CG, Khoutorsky A, Ran I, Rampakakis E, Nevarko T, Weatherill DB, Vasuta C, Yee S, Truitt M, Dallaire P, Major F, Lasko P, Ruggero D, Nader K, Lacaille JC, Sonenberg N (2013) Autism-related deficits via dysregulated elf4E-dependent translational control. Nature 493:371–377

Golzio C, Willer J, Talkowski ME, Oh EC, Taniguchi Y, Jacquemont S, Reymond A, Sun M, Sawaw A, Gusella JF, Kamiya I, Beckmann JS, Katsanis N (2012) KCTD13 is a major driver of mirrored neuroanatomical phenotypes of the 16p11.2 copy number variant. Nature 485:363–367

Hansen DV, Rubenstein JL, Kriegstein AR (2011) Deriving excitatory neurons of the neocortex from pluripotent stem cells. Neuron 70: 645–660

Henrichsen CN, Chaignat E, Reymond A (2009a) Copy number variants, diseases and gene expression. Hum Mol Genet 18:R1–R8

Henrichsen CN, Vinckenbosch N, Zollner S, Chaignat E, Pradervand S, Schutz F, Ruedi M, Kaesemann H, Reymond A (2009b) Segmental copy number variation shapes tissue transcriptomes. Nat Genet 41: 424–429

Hester ME, Murtha MJ, Song S, Rao M, Miranda CJ, Meyer K, Tian J, Boulling G, Schaffer DV, Zhu MX, Pfaff SL, Gage FH, Kaspar BK (2011) Rapid and efficient generation of functional motor neurons from human pluripotent stem cells using gene delivered transcription factor codes. Mol Ther 19:1005–1012

Hogart A, Wu D, LaSalle JM, Schanen NC (2010) The comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13. Neurobiol Dis 38:181–191

Hu BY, Weick JP, Yu J, Ma LX, Zhang XQ, Thomson JA, Zhang SC (2010) Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci U S A 107:4335–4340

Huang ZJ, Di Cristo G, Ango F (2007) Development of GABA innervation of migratory neurons and is involved in neuronal maturation rather than action-dependent dendritic retraction in rodent and human neurons. Nat Neurosci 10:733–739

Huang ZJ, Di Cristo G, Ango F (2007) Development of GABA innervation of migratory neurons and is involved in neuronal maturation rather than action-dependent dendritic retraction in rodent and human neurons. Nat Neurosci 10:733–739

Kellerh RJ 3rd, Bear MF (2008) The autistic neuron: troubled translational control. Nature 493:371–377

Kim Y, Kweon J, Kim A, Chon JK, Yoo JY, Kim HJ, Kim S, Lee C, Jeong HM (2011) RNA-Seq of human neurons derived from iPS cells reveals candidate long non-coding RNAs involved in neurogenesis and neuropsychiatric disorders. PLoS One 6:e23356

Kober GM, Morin R, Ballinger S, Fu Y, Panagiotou A, Dziejman M, Garcia-Neves P, Bouzaid AM, Lim ET, Raychaudhuri S, Sanders SJ, Stevens C, Sabo A, MacArthur DG, Neale BM, Kirby A, Ruderfer DM, Fromer M, Lek M, Liu L, Flamack J, Ripke S, Nagaswamy U, Muzny D, Reid JG, Hawes A, Newsham I, Wu Y, Lewis L, Dinah H, Gross S, Wang LS, Lin CF, Valladares O, Gabriel SB, dePristoe M, Alshuler DM, Purcell SM, State MW, Boerwinkle E, Buxbaum JD, Cook EH, Gibbs RA, Schellenberg GD, Sutcliffe JS, Devlin B, Roeder K, Daly MJ (2013) Rare complete knockout in humans: population distribution and significant role in autism spectrum disorders. Nature 77:235–242

Kondo K, Araki M, Yamada M, Tanaka H, Tanino M, Uchida T, Kato T, Saito K, Kajii T, Yamashita Y, Sagara Y, Kinoshita S, Shimizu S, Nakajima Y, Takei S (2013) Probing sporadic and familial Autism spectrum disorders. PLoS Genet 8:e1002521

Koryak T, Zheludkevich EA, Gavrilova N, Ferec C, Martin CL, Duvall JA, Ilkin Y, Simon JS, Arreaza MG, Wilkes K, Lemaire N, Skuse D, Pott M, Holt R, Monaco AP, Jarvela I, Kanotjarvi K, Vanhala R, Curran S, Collier DA, Bolton P, R Cool E, Jaenisch R (2013) Knockout and conditional gene deletion in human ES and iPS cells regardless of their innate differentiation propensity. Stem Cell Rev 6:270–281

Kralik JD, Jaworski K, Sukumar N, Clatworthy R, Sorensen S, Simms B, Youn J, Brinkman R, Ebersole JL, Navia BA, Colby DD, Shi B, Young RA, Jaenisch R (2013) Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. Cell Stem Cell 13:446–458

Kriks S, Shin JW, Piao J, Ganat YM, Wakeman DR, Xie Z, Carrillo-Reid L, Auyeung G, Antonacci C, Buch A, Yang L, Beal MF, Surmeier DJ, Kordover JH, Tabar V, Studer L (2011) Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature 480:547–551
McMahon FJ, Malhotra AK, Potash JB, Schulze TG, Nothen MM, Cichon S, Rietschel M, Leibenthal E, Kustanovich V, Lajونчже CM, Sutcliffe JS, Skuse D, Gill M, Gallagher L, Mendell NR, Craddock N, Owen MJ, O’Donovan MC, Shaikh TH, Susser E, Delisi LE, Sullivan PF, Deutsch CK, Rapoport J, Levy DL, King MC, Sebat J (2009) Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet 41:1223–1227

Merla G, Brunetti-Pierri N, Micale L, Fusco C (2010) Copy number variants at Williams-Beuren syndrome 7q11.23 region. Hum Genet 128:3–26

Mervis CB, John AE (2010) Cognitive and behavioral characteristics of children with Williams syndrome: implications for intervention approaches. Am J Med Genet C Semin Med Genet 154C:229–248

Michaelson JJ, Shi Y, Gujral M, Zheng H, Malhotra D, Jin X, Jian M, Liu G, Greer D, Bhandari A, Wu W, Corinonas R, Peoples A, Koren A, Gore A, Kang S, Lin GN, Estabillo J, Gadjonski T, Singh B, Zhang K, Akshoomoff N, Corsello C, McCarroll S, Iakoucheva LM, Li Y, Wang J, Sebat J (2012) Whole-genome sequencing in autism identifies hot spots for de novo germine mutation. Cell 151:1431–1442

Michalson A, Sidorov M, Ballard TM, Ozmen L, Sporen W, Wettstein JG, Jaeschke G, Bear MF, Lindemann L (2012) Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74: 49–56

Myers SM, Johnson CP (2007) Management of children with autism spectrum disorders. Pediatrics 120:1162–1182

Neale BM, Kou Y, Liu L, Ma’ayan A, Consiglio A, Richard Y, Rodriguez-Piza I, Devlin B, Edel M, Bove J, Memo M, Vila R, Aya R, Ispiau Belmonte JC (2012a) Efficient generation of A9 midbrain dopaminergic neurons by lentiviral delivery of LMX1A in human embryonic stem cells and induced pluripotent stem cells. Hum Gene Ther 23:56–69

Sanchez-Danes A, Richard-Patiñ Y, Carballo-Carbajal I, Jimenez-Delgado S, Caig C, Mora S, Di Guglielmo C, Ezquerra M, Patel B, Giralt A, Canals JM, Memo M, Alberch J, Lopez-Barneja V, Vila M, Cuervo AM, Tolosa E, Consiglio A, Aya R (2012b) Disease-specific phenotypes in dopamine neurons from human iPSC-based models of genetic and sporadic Parkinson’s disease. EMBO Mol Med 4:380–395

Sanders SJ, Erkan-Sencicek AG, Hus V, Luo R, Mutha MT, Moreno-De-Lucena D, Chu SH, Moreau MP, Gupta AR, Thomson SA, Mason CE, Bilguvar K, Celestino-Soper PB, Choi M, Crawford EL, Davis L, Wright NR, Dhodapkar RM, DiCola M, DiLullo NM, Fernandez TV, Fielding-Singh V, Fishman DO, Frahim S, Garagaloyan R, Goh GS, Kammler S, Klei L, Lowe JK, Lund SC, McGrew AD, Meyer KA, Moffat WJ, Murdoch JD, O’Roak BJ, Ober GT, Pottinger RS, Raubeson M, Song Y, Wang Q, Yaspang BL, Yu TW, Yurkiewicz IR, Beaudet AL, Cantor RM, Curland M, Grice DE, Gunel M, Lifton RP, Mane SM, Martin DM, Shaw CA, Sheldon M, Tischfield JA, Walsh CA, Morrow EM, Ledbetter DH, Fombonne E, Lord C, Martin CL, Brooks AL, Sutcliffe JS, Cook EH Jr, Geschwind D, Roeder K, Devlin B, State MW (2011) Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron 70:863–885

Santini E, Huynh TN, MacAskill AF, Carter AG, Pierre P, Ruggero D, Kaphzan H, Klann E (2013) Exaggerated translation causes synaptic and behavioural aberrations associated with autism. Nature 493: 411–415

Schaf C, Zoghbi HY (2011) Solving the autism puzzle a few pieces at a time. Neuron 70:863–885

Schunk CM, Nodahl CW (2011) Bridging the gap between MRI and postmortem research in autism. Brain Res 1380:175–186

Seki T, Yasuda S, Fukuda E, Russell K (2011) Developmental vulnerability of synapses and circuits associated with neuropsychiatric disorders. J Neurochem 126:165–182

Pura MF, Andrade J, Houssam S, Reubinoff B, Trabouso A, Stanely EG, Ward-van Oostwaard D, Mummery C (2004) Regression of human embryonic stem cell differentiation by BMP-2 and its antagonist noggin. J Cell Sci 117:1269–1280

Phelan K, McDermid HE (2012) The 22q13.13 deletion syndrome (Phelan-McDermid syndrome). Mol Syndromol 3(5):186–201

Qiang L, Fujita R, Yamashita T, Angulo S, Rhinn H, Rhee D, Doogle C, Chau L, Aubry L, Vanti WB, Moreno H, Abelovich A (2011) Directed conversion of Alzheimer’s disease patient skin fibroblasts into functional neurons. Cell 146:359–371

Reynold A, Henrichsen CN, Harewood L, Merla G (2007) Side effects of genome structural changes. Curr Opin Genet Dev 17:381–386

Sanchez-Danes A, Consiglio A, Richard Y, Rodriguez-Piza I, Devlin B, Edel M, Bove J, Memo M, Vila R, Aya R, Ispiau Belmonte JC (2012a) Efficient generation of A9 midbrain dopaminergic neurons by lentiviral delivery of LMX1A in human embryonic stem cells and induced pluripotent stem cells. Hum Gene Ther 23:56–69

Sanchez-Danes A, Richard-Patin Y, Carballo-Carbajal I, Jimenez-Delgado S, Caig C, Mora S, Di Guglielmo C, Ezquerra M, Patel B, Giralt A, Canals JM, Memo M, Alberch J, Lopez-Barneja V, Vila M, Cuervo AM, Tolosa E, Consiglio A, Aya R (2012b) Disease specific phenotypes in dopamine neurons from human iPSC-based models of genetic and sporadic Parkinson’s disease. EMBO Mol Med 4:380–395

Sanders SJ, Erkan-Sencicek AG, Hus V, Luo R, Mutha MT, Moreno-De-Lucena D, Chu SH, Moreau MP, Gupta AR, Thomson SA, Mason CE, Bilguvar K, Celestino-Soper PB, Choi M, Crawford EL, Davis L, Wright NR, Dhodapkar RM, DiCola M, DiLullo NM, Fernandez TV, Fielding-Singh V, Fishman DO, Frahim S, Garagaloyan R, Goh GS, Kammler S, Klei L, Lowe JK, Lund SC, McGrew AD, Meyer KA, Moffat WJ, Murdoch JD, O’Roak BJ, Ober GT, Pottinger RS, Raubeson M, Song Y, Wang Q, Yaspang BL, Yu TW, Yurkiewicz IR, Beaudet AL, Cantor RM, Curland M, Grice DE, Gunel M, Lifton RP, Mane SM, Martin DM, Shaw CA, Sheldon M, Tischfield JA, Walsh CA, Morrow EM, Ledbetter DH, Fombonne E, Lord C, Martin CL, Brooks AL, Sutcliffe JS, Cook EH Jr, Geschwind D, Roeder K, Devlin B, State MW (2011) Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron 70:863–885

Santini E, Huynh TN, MacAskill AF, Carter AG, Pierre P, Ruggero D, Kaphzan H, Klann E (2013) Exaggerated translation causes synaptic and behavioural aberrations associated with autism. Nature 493: 411–415

Schaf C, Zoghbi HY (2011) Solving the autism puzzle a few pieces at a time. Neuron 70:806–808

Schumm CM, Nodahl CW (2011) Bridging the gap between MRI and postmortem research in autism. Brain Res 1380:175–186

Seki T, Yasuda S, Fukuda E, Russell K (2011) Development of induced pluripotent stem cells from human peripheral circulating T cells. Curr Protoc Stem Cell Biol Chapter 4: Unit4A3

Shandai V, Sundaram SK, Chuang DC, Kumar A, Behen ME, Chunga HT (2011) Abnormal brain protein synthesis in language areas of children with pervasive developmental disorder: a 14C-labeled leucine PET study. J Child Neurol 26:1347–1354

Shchegliovitov A, Shchegliovitova O, Yazawa M, Portmann T, Shandal V, Sebastian V, Krawisz A, Frielich W, Bernstein JA, Hallmayer JF, Dolmetsch RE (2013) SHANK3 and IGF1 restore synaptic deficits in neurons from 22q11 deletion syndrome patients. Nature. doi:10.1038/nature12618

Springer
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2006) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872

Shi Y, Kirwan P, Livesey FJ (2012a) Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat Protoc 7:1836–1846

Shi Y, Kirwan P, Smith J, MacLean G, Orkin SH, Livesey FJ (2012b) A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci Transl Med 4:124–ra129

Shi Y, Kirwan P, Smith J, Robinson HP, Livesey FJ (2012c) Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat Neurosci 15:477–486, S471

Silverman JL, Smith DG, Rizzo SJ, Karras MN, Turner SM, Tolu SS, Bryce DK, Smith DL, Fonseca K, King RH, Crawley JN (2012) Negative allostatic modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci Transl Med 4:131ra51

Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, Napolitano C, Schwartz PJ, Joseph RM, Condouris K, Tager-Flusberg H, Priori SG, Sanguinetti MC, Keating MT (2005) Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 119:19–31

Splawski I, Timothy KW, Decher N, Kumar P, Sachse FB, Beggs AH, Sanguinetti MC, Keating MT (2005) Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci U S A 102:8089–8096, discussion 8086–8088

Splawski I, Timothy KW, Priori SG, Napolitano C, Bloise R (2006) Timothy Syndrome. In: Pagon RABT, Dolan CR, Stephens K, Adam MP (eds) GeneReviews™ [Internet]. University of Washington, Seattle

Steffenberg S, Gillberg C, Hellgren L, Andersson L, Gillberg IC, Jakobsson G, Bohman M (1989) A twin study of autism in Denmark, Finland, Iceland, Norway and Sweden. J Child Psychol Psychiatry 30:405–416

Stein JL, Parikshak NN, Geschwind DH (2013) Rare inherited variation in autism: beginning to see the forest and a few trees. Neuron 77:209–211

Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676

Takahashi K, Tanabe K, Ohmuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872

Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, Fu DD, Flannery R, Jaenisch R, Sur M (2009) Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A 106:2029–2034

Urbach A, Bar-Nur O, Daley GQ, Benvenisty N (2010) Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 6:407–411

Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhoff TC, Wernig M (2010) Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463:1035–1041

Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S, Mill J, Cantor RM, Blencowe BJ, Geschwind DH (2011) Transcriptomic analysis of autist brain reveals convergent molecular pathology. Nature 474:380–384

Williams CA, Beaudet AL, Clayton-Smith J, Knoll JH, Kyllerman M, Lai LA, Magenis RE, Moncla A, Schinzel AA, Summers JA, Wagstaff J (2006) Angelman syndrome 2005: updated consensus for diagnostic criteria. Am J Med Genet A 140:413–418

Xiao A, Wu Y, Yang Z, Hu Y, Wang W, Zhang Y, Kong L, Gao G, Zhu Z, Lin S, Zhang B (2013) EENdb: a database and knowledge base of ZFNs and TALENs for endonuclease engineering. Nucleic Acids Res 41:D415–D422

Yazdani M, Deogracias R, Guy J, Poot RA, Bird A, Barde YA (2012) Disease modeling using embryonic stem cells: MeCP2 regulates nuclear size and RNA synthesis in neurons. Stem Cells 30:2128–2139

Yu TW, Chahrour MH, Coulter ME, Jiralerspong S, Okamura-Ikeda K, Lin S, Zhang B (2013) EENdb: a database and knowledge base of ZFNs and TALENs for endonuclease engineering. Nucleic Acids Res 41:D415–D422

Yuan SH, Martin J, Elia J, Flippin J, Paramban RI, Heffernan MP, Vidal JG, Mu Y, Killian RL, Israel MA, Emre N, Marsala S, Marsala M, Gage FH, Goldstein LS, Carson CT (2011) Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS One 6:e17540

Zhou T, Benda C, Dunzinger S, Huang Y, Li X, Li Y, Guo X, Cao G, Chen S, Hao L, Chan YC, Ng KM, Ho JC, Wieser M, Wu J, Redl H, Tse HF, Grillari J, Grillari-Voglauer R, Pei D, Esteban MA (2011) Generation of induced pluripotent stem cells from urine. J Am Soc Nephrol 22:1221–1228

Zhou T, Benda C, Dunzinger S, Huang Y, Ho JC, Yang J, Wang Y, Zhang Y, Zhu Q, Li Y, Bao X, Tse HF, Grillari J, Grillari-Voglauer R, Pei D, Esteban MA (2012) Generation of human induced pluripotent stem cells from urine samples. Nat Protoc 7:2080–2089